225 related articles for article (PubMed ID: 34850325)
1. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial.
Meng F; Zhao J; Tan AT; Hu W; Wang SY; Jin J; Wu J; Li Y; Shi L; Fu JL; Yu S; Shen Y; Liu L; Luan J; Shi M; Xie Y; Zhou CB; Wong RW; Lu-En W; Koh S; Bertoletti A; Wang T; Zhang JY; Wang FS
Hepatol Int; 2021 Dec; 15(6):1402-1412. PubMed ID: 34850325
[TBL] [Abstract][Full Text] [Related]
2. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial.
Yang F; Zheng X; Koh S; Lu J; Cheng J; Li P; Du C; Chen Y; Chen X; Yang L; Chen W; Wong RW; Wai LE; Wang T; Zhang Q; Chen W
Hepatol Int; 2023 Aug; 17(4):850-859. PubMed ID: 37067675
[TBL] [Abstract][Full Text] [Related]
3. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
4. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC.
Tan AT; Meng F; Jin J; Zhang JY; Wang SY; Shi L; Shi M; Li Y; Xie Y; Liu LM; Zhou CB; Chua A; Ho ZZ; Luan J; Zhao J; Li J; Wai LE; Koh S; Wang T; Bertoletti A; Wang FS
Hepatol Commun; 2022 Apr; 6(4):841-854. PubMed ID: 34935312
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
Qasim W; Brunetto M; Gehring AJ; Xue SA; Schurich A; Khakpoor A; Zhan H; Ciccorossi P; Gilmour K; Cavallone D; Moriconi F; Farzhenah F; Mazzoni A; Chan L; Morris E; Thrasher A; Maini MK; Bonino F; Stauss H; Bertoletti A
J Hepatol; 2015 Feb; 62(2):486-91. PubMed ID: 25308176
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients.
Hafezi M; Lin M; Chia A; Chua A; Ho ZZ; Fam R; Tan D; Aw J; Pavesi A; Krishnamoorthy TL; Chow WC; Chen W; Zhang Q; Wai LE; Koh S; Tan AT; Bertoletti A
Hepatology; 2021 Jul; 74(1):200-213. PubMed ID: 33249625
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
8. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
10. Genetically redirected HBV-specific T cells target HBsAg-positive hepatocytes and primary lesions in HBV-associated HCC.
Wan X; Wisskirchen K; Jin T; Yang L; Wang X; Wu X; Liu F; Wu Y; Ma C; Pang Y; Li Q; Zhang K; Protzer U; Du S
Clin Mol Hepatol; 2024 May; ():. PubMed ID: 38808361
[TBL] [Abstract][Full Text] [Related]
11. Association Between High-Avidity T-Cell Receptors, Induced by α-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma.
Nakagawa H; Mizukoshi E; Kobayashi E; Tamai T; Hamana H; Ozawa T; Kishi H; Kitahara M; Yamashita T; Arai K; Terashima T; Iida N; Fushimi K; Muraguchi A; Kaneko S
Gastroenterology; 2017 May; 152(6):1395-1406.e10. PubMed ID: 28188748
[TBL] [Abstract][Full Text] [Related]
12. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.
Gehring AJ; Xue SA; Ho ZZ; Teoh D; Ruedl C; Chia A; Koh S; Lim SG; Maini MK; Stauss H; Bertoletti A
J Hepatol; 2011 Jul; 55(1):103-10. PubMed ID: 21145860
[TBL] [Abstract][Full Text] [Related]
13. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
Gao Y; Guo J; Bao X; Xiong F; Ma Y; Tan B; Yu L; Zhao Y; Lu J
Oncologist; 2021 Nov; 26(11):e1919-e1930. PubMed ID: 34255901
[TBL] [Abstract][Full Text] [Related]
14. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
15. Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
Tan AT; Schreiber S
Antiviral Res; 2020 Apr; 176():104748. PubMed ID: 32087191
[TBL] [Abstract][Full Text] [Related]
16. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
Front Immunol; 2020; 11():623. PubMed ID: 32425926
[TBL] [Abstract][Full Text] [Related]
17. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.
Lee SWL; Adriani G; Ceccarello E; Pavesi A; Tan AT; Bertoletti A; Kamm RD; Wong SC
Front Immunol; 2018; 9():416. PubMed ID: 29559973
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
19. Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood.
Lin M; Bhakdi SC; Tan D; Lee JJX; Tai DWM; Pavesi A; Wai LE; Wang T; Bertoletti A; Tan AT
Immunother Adv; 2023; 3(1):ltad015. PubMed ID: 37636242
[TBL] [Abstract][Full Text] [Related]
20. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
Shiah HS; Chen CY; Dai CY; Hsiao CF; Lin YJ; Su WC; Chang JY; Whang-Peng J; Lin PW; Huang JD; Chen LT
Aliment Pharmacol Ther; 2013 Jan; 37(1):62-73. PubMed ID: 23134470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
